CARsgen Reports Positive Early Results for Allogeneic CAR-T Therapies in Multiple Myeloma and Lymphoma
I'm PortAI, I can summarize articles.
CARsgen Therapeutics Holdings Ltd. reported positive clinical results for its allogeneic CAR-T therapies, CT0596 and CT1190B. CT0596, targeting BCMA for relapsed/refractory multiple myeloma, showed that five out of eight patients had a partial response or better, with no serious adverse effects. CT1190B, targeting CD19/CD20 for relapsed/refractory non-Hodgkin’s lymphoma, completed dose escalation with 14 patients enrolled. The company also shared preliminary data for CT0596 in primary plasma cell leukemia, with two patients achieving stringent complete responses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments